Clorox (CLX) is trading lower today after a new analyst reset added to a cautious setup into next week’s earnings. Morgan Stanley lowered its price target to $110 from $136 while maintaining an Equalweight stance, a sizable cut that can pressure sentiment in a stock already trading defensively into a catalyst.

A large target reduction signals softer confidence in near-term upside and can trigger de-risking by investors who rely on consensus valuation frameworks. The downgrade/target-cut cycle has intensified recently, including JPMorgan’s move to Underweight with a $99 target ahead of fiscal Q3 2026 results, reinforcing the narrative that cost pressures and execution risk could keep returns constrained.

The next major catalyst is Clorox’s scheduled earnings release on April 30, 2026. Traders will focus on commentary around pricing versus volume, margin trajectory amid cost pressures, and whether operational improvements translate into cleaner demand trends—any disappointment could keep the stock under pressure, while a resilient outlook could stabilize sentiment.